The Potential for Pharmacokinetic Interactions Between Cannabis Products and Conventional Medications.

@article{Qian2019ThePF,
  title={The Potential for Pharmacokinetic Interactions Between Cannabis Products and Conventional Medications.},
  author={Yuli Qian and Bill J Gurley and John Seth Markowitz},
  journal={Journal of Clinical Psychopharmacology},
  year={2019}
}
PURPOSE Increased cannabis use and recent drug approvals pose new challenges for avoiding drug interactions between cannabis products and conventional medications. This review aims to identify drug-metabolizing enzymes and drug transporters that are affected by concurrent cannabis use and, conversely, those co-prescribed medications that may alter the exposure to one or more cannabinoids. METHODS A systematic literature search was conducted utilizing the Google Scholar search engine and… 
The Pharmacodynamics, Pharmacokinetics, and Potential Drug Interactions of Cannabinoids
TLDR
In this chapter, what is known about drug-drug interactions and their clinical significance are reviewed and an understanding of the pharmacokinetics of both the “victim” drug and cannabis is explored.
Potential Adverse Drug Events with Tetrahydrocannabinol (THC) Due to Drug–Drug Interactions
TLDR
Clinicians should balance the potential risks of THC and cannabis and the lack of strong evidence of efficacy in many conditions with patient desires for alternative therapy, and many interactions may be unavoidable, dose-limiting, or a barrier to THC-based therapy.
Clinical Relevance of Drug Interactions with Cannabis: A Systematic Review
TLDR
Evidence is provided for both the low probability of the occurrence of clinically relevant drug interactions and the lack of evidence regarding cannabis–drug interactions.
Potential Pharmacokinetic Drug-Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain
TLDR
This brief review is to assess the interactions between cannabinoids and pain medication through drug transporters (ATP-binding cassette superfamily members) and/or metabolizing enzymes (cytochromes P450 and glucuronyl transferases).
A Review of Cannabis and Interactions With Anticoagulant and Antiplatelet Agents
Legalization of medical cannabis has occurred in 33 states and the District of Columbia, and recreational use has increased exponentially since 2013. As a result, it is important to understand how
Special Section on Natural Products: Experimental Approaches to Elucidate Disposition Mechanisms and Predict Pharmacokinetic Drug Interactions — Minireview Natural Products as Modulators of CES1 Activity
TLDR
The results of a systematic literature search are reported and natural products as potential modulators of CES1 activity are discussed and challenges and future directions in this field are outlined.
Natural and Synthetic Cannabinoids: Pharmacology, Uses, Adverse Drug Events, and Drug Interactions
TLDR
This review provides a summary of approved uses and an overview of mechanisms of action for adverse drug events with natural and synthetic cannabinoids, and clinical considerations for special populations that may be at heightened risk for drug‐drug interactions and adverse drugs events while using natural or synthetic cannabinoids.
The Impact of Marijuana on Antidepressant Treatment in Adolescents: Clinical and Pharmacologic Considerations
TLDR
Clinicians should discuss THC and CBD use in youth prescribed SSRIs and be aware of the impact of initiating, stopping, or decreasing cannabinoid use as this may significantly affect es/citalopram and sertraline exposure.
Natural Products as Modulators of CES1 Activity
TLDR
The natural products that can potentially interact with CES1 substrate medications are summarized and the modulatory effects on CES1 expression after chronic exposure to natural products warrants further investigation.
Translational models of cannabinoid vapor exposure in laboratory animals
TLDR
This review examines the emerging field of preclinical vapor models with a focus on cannabinoid exposure to discuss the pharmacological and behavioral effects produced by exposure to vaporized cannabinoids, and compare behavioral effects of cannabinoid vapor administration with those of other routes of administration.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 79 REFERENCES
In Vitro Inhibition of Carboxylesterase 1 by Major Cannabinoids and Selected Metabolites
TLDR
In this study, in vitro inhibitory effects of the individual major cannabinoids and metabolites ∆9-tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), 11-nor-THC-carboxylic acid, and 11-hydroxy- THC on CES1 activity were investigated.
Human Cannabinoid Pharmacokinetics
  • M. Huestis
  • Biology, Chemistry
    Chemistry & biodiversity
  • 2007
TLDR
The cardiovascular and subjective effects of cannabis are blocked by rimonabant, the first CB-1 cannabinoid-receptor antagonist, documenting thatCB-1 receptors mediate these effects of smoked cannabis in humans.
Interaction between warfarin and cannabis
TLDR
A case report of a 27-year-old man treated with warfarin due to mechanical heart valve replacement who presented with elevated international normalized ratio (INR) value ( INR = 4.6) following recreational cannabis use is described.
Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel.
TLDR
Coadministration of medicinal cannabis, as herbal tea, in cancer patients treated with irinotecan or docetaxel does not significantly influence the plasma pharmacokinetic parameters with and without concomitant medicinal cannabis.
Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration.
TLDR
Human whole-blood cannabinoid data following cannabis smoking will assist whole blood and plasma cannabinoid interpretation, while furthering identification of recent cannabis intake.
Free and Glucuronide Whole Blood Cannabinoids' Pharmacokinetics after Controlled Smoked, Vaporized, and Oral Cannabis Administration in Frequent and Occasional Cannabis Users: Identification of Recent Cannabis Intake.
TLDR
Blood pharmacokinetics of THC, its phase I and phase II glucuronide metabolites, and minor cannabinoids are characterized in occasional and frequent cannabis smokers for 54 and 72 hours after controlled smoked, vaporized, and oral cannabis administration to improve interpretation of cannabinoid tests.
Exogenous Cannabinoid Efficacy: Merely a Pharmacokinetic Interaction?
TLDR
The key pharmacological knowledge required to guide further exploration of the toxicity and efficacy of different cannabinoids and their formulations in blinded placebo-controlled studies are covered.
...
1
2
3
4
5
...